Today, Beijing Daxiang Technology Co., Ltd., a biotechnology company focused on developing Organ on a Chip, announced the completion of a 10 million yuan angel round financing. This round of financing is led by WuXi KangDe, with JiuYou Capital and FuRong Investment participating in the investment. With this funding, Daxiang Technology will further develop and optimize organ chip models, providing tools that balance biomimetics and high-throughput for innovative drug research and development, and accelerating the drug development process Conventional preclinical research and development of new drugs require the use of 2D in vitro cell models and animal models. However, due to the technical limitations of the models, over 90% of drugs exhibit differentiated mechanisms, toxicity, and efficacy in real human environments, resulting in drug development failures and waste of financial time

As a burgeoning new technology in recent years, organ chip, which ingeniously combines micro processing technology and cell biology, can accurately control the cell microenvironment, simulate the structure and functional units of organs in vitro, and is expected to become a sharp tool to solve the pain points of existing model technology. Compared with the traditional 2D cell model, the organ chip model can better reflect the key physiological characteristics of the micro physiological system of human organ; At the same time, it also solves the drug development problems caused by species differences in animal models to a certain extent. Therefore, Nature Reviews Materials pointed out in a review last year that organ chips can help us "understand the effectiveness of drugs and improve preclinical safety and efficacy testing". The US FDA and some internationally renowned pharmaceutical companies have launched a series of research and development collaborations with organ chip companies to evaluate the significance of this technology for new drug screening In China, the field of organ chips is mostly in the scientific research stage, and Da Xiang Technology is one of the few emerging companies that has entered the industry and gradually matured. Its current products are mainly used in the research and development of anti-tumor drugs. Three organ chip platforms have been developed, on which different models can be constructed to meet the research and development needs of different drugs Mr. Zhou Yu, co-founder of Da Xiang Technology, said: "I am very pleased that Da Xiang Technology's skills have been recognized by WuXi KangDe, JiuYou Capital, and Shanghai Fu Rong. This round of investment will help Da Xiang Technology complete its existing research products and promote them to the market. Looking forward to the future, we will be committed to promoting and leading the widespread application of organ chip technology in new drug research and development, medical research, and personalized healthcare, making contributions to the development of human health

Reference:

[1] Boyang Zhang et al., (2018), Advances in organ-on-a-chip engineering, Nature Reviews Materials, DOI: < a href=" https://doi.org/10.1038/s41578-018-0034-7 "> https://doi.org/10.1038/s41578-018-0034-7

[2] ORGANS-ON-CHIPS TECHNOLOGY, Retrieved November 4, 2019, from < a href=" https://www.fda.gov/media/104288/download "> https://www.fda.gov/media/104288/download

[3] Park et al., Organoids-on-a-chip. Science 364, 960–965 (2019) 7,June 2019.